An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer

In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-05, Vol.14 (5), p.e25496-e25496
Main Authors: Miyaki, Candace, Lynch, Launa M
Format: Article
Language:English
Subjects:
Adenosine
Antidiabetics
Beta blockers
Cancer therapies
Cohort analysis
Diabetes
Disease prevention
Endocrinology/Diabetes/Metabolism
Epidermal growth factor
Kinases
Medical prognosis
Meta-analysis
Obesity
Oncology
Pancreatic cancer
Pharmaceuticals
Preventive Medicine
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23
cites cdi_FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23
container_end_page e25496
container_issue 5
container_start_page e25496
container_title Curēus (Palo Alto, CA)
container_volume 14
creator Miyaki, Candace
Lynch, Launa M
description In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of pancreatic cancer incidence. However, in recent studies, these medications along with combination therapy of aspirin and metformin were found to have a more significant association with decreasing risk. Given the poor prognosis of pancreatic cancer despite treatment, medication prophylaxis prevention should be considered. In this review, we hope to encourage future case-control or prospective studies on common medications that have shown great potential in delaying pancreatic cancer development.
doi_str_mv 10.7759/cureus.25496
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9246430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2687722264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23</originalsourceid><addsrcrecordid>eNpdkU9LAzEUxIMottTe_AALXjy4NXnZbJKLUIp_KdiDPYc0TeyW7qYmuwW_vaktop5m4P0Y5jEIXRI84pzJW9MF28URsEKWJ6gPpBS5IKI4_eV7aBjjGmNMMAfM8TnqUSYwFoD76GXcZPPtUrc280028XWdZLbSodbGdm1l9CZmVZO1K5vNgt3Zpq0S4V02040JVickmyRrwwU6c4m2w6MO0Pzh_m3ylE9fH58n42luKJFtzsBJJ4ERyeiCaiBOF1wyYNJQLkxRMkeEKSU4Tp0tUm-nBdaacyklWwIdoLtD7rZb1HZpUqWgN2obqlqHT-V1pf5emmql3v1OSSjKguIUcH0MCP6js7FVdRWN3Wx0Y30XFZSCcwBI8ABd_UPXvgtNei9RsuQCoNhTNwfKBB9jsO6nDMFqv5M67KS-d6JfIkyENQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696782244</pqid></control><display><type>article</type><title>An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Miyaki, Candace ; Lynch, Launa M</creator><creatorcontrib>Miyaki, Candace ; Lynch, Launa M</creatorcontrib><description>In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of pancreatic cancer incidence. However, in recent studies, these medications along with combination therapy of aspirin and metformin were found to have a more significant association with decreasing risk. Given the poor prognosis of pancreatic cancer despite treatment, medication prophylaxis prevention should be considered. In this review, we hope to encourage future case-control or prospective studies on common medications that have shown great potential in delaying pancreatic cancer development.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.25496</identifier><identifier>PMID: 35800820</identifier><language>eng</language><publisher>Palo Alto: Cureus Inc</publisher><subject>Adenosine ; Antidiabetics ; Beta blockers ; Cancer therapies ; Cohort analysis ; Diabetes ; Disease prevention ; Endocrinology/Diabetes/Metabolism ; Epidermal growth factor ; Kinases ; Medical prognosis ; Meta-analysis ; Obesity ; Oncology ; Pancreatic cancer ; Pharmaceuticals ; Preventive Medicine ; Vascular endothelial growth factor</subject><ispartof>Curēus (Palo Alto, CA), 2022-05, Vol.14 (5), p.e25496-e25496</ispartof><rights>Copyright © 2022, Miyaki et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Miyaki et al. 2022 Miyaki et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23</citedby><cites>FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2696782244/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2696782244?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Miyaki, Candace</creatorcontrib><creatorcontrib>Lynch, Launa M</creatorcontrib><title>An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer</title><title>Curēus (Palo Alto, CA)</title><description>In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of pancreatic cancer incidence. However, in recent studies, these medications along with combination therapy of aspirin and metformin were found to have a more significant association with decreasing risk. Given the poor prognosis of pancreatic cancer despite treatment, medication prophylaxis prevention should be considered. In this review, we hope to encourage future case-control or prospective studies on common medications that have shown great potential in delaying pancreatic cancer development.</description><subject>Adenosine</subject><subject>Antidiabetics</subject><subject>Beta blockers</subject><subject>Cancer therapies</subject><subject>Cohort analysis</subject><subject>Diabetes</subject><subject>Disease prevention</subject><subject>Endocrinology/Diabetes/Metabolism</subject><subject>Epidermal growth factor</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Obesity</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><subject>Pharmaceuticals</subject><subject>Preventive Medicine</subject><subject>Vascular endothelial growth factor</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU9LAzEUxIMottTe_AALXjy4NXnZbJKLUIp_KdiDPYc0TeyW7qYmuwW_vaktop5m4P0Y5jEIXRI84pzJW9MF28URsEKWJ6gPpBS5IKI4_eV7aBjjGmNMMAfM8TnqUSYwFoD76GXcZPPtUrc280028XWdZLbSodbGdm1l9CZmVZO1K5vNgt3Zpq0S4V02040JVickmyRrwwU6c4m2w6MO0Pzh_m3ylE9fH58n42luKJFtzsBJJ4ERyeiCaiBOF1wyYNJQLkxRMkeEKSU4Tp0tUm-nBdaacyklWwIdoLtD7rZb1HZpUqWgN2obqlqHT-V1pf5emmql3v1OSSjKguIUcH0MCP6js7FVdRWN3Wx0Y30XFZSCcwBI8ABd_UPXvgtNei9RsuQCoNhTNwfKBB9jsO6nDMFqv5M67KS-d6JfIkyENQ</recordid><startdate>20220530</startdate><enddate>20220530</enddate><creator>Miyaki, Candace</creator><creator>Lynch, Launa M</creator><general>Cureus Inc</general><general>Cureus</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220530</creationdate><title>An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer</title><author>Miyaki, Candace ; Lynch, Launa M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenosine</topic><topic>Antidiabetics</topic><topic>Beta blockers</topic><topic>Cancer therapies</topic><topic>Cohort analysis</topic><topic>Diabetes</topic><topic>Disease prevention</topic><topic>Endocrinology/Diabetes/Metabolism</topic><topic>Epidermal growth factor</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Obesity</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><topic>Pharmaceuticals</topic><topic>Preventive Medicine</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyaki, Candace</creatorcontrib><creatorcontrib>Lynch, Launa M</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyaki, Candace</au><au>Lynch, Launa M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><date>2022-05-30</date><risdate>2022</risdate><volume>14</volume><issue>5</issue><spage>e25496</spage><epage>e25496</epage><pages>e25496-e25496</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of pancreatic cancer incidence. However, in recent studies, these medications along with combination therapy of aspirin and metformin were found to have a more significant association with decreasing risk. Given the poor prognosis of pancreatic cancer despite treatment, medication prophylaxis prevention should be considered. In this review, we hope to encourage future case-control or prospective studies on common medications that have shown great potential in delaying pancreatic cancer development.</abstract><cop>Palo Alto</cop><pub>Cureus Inc</pub><pmid>35800820</pmid><doi>10.7759/cureus.25496</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2022-05, Vol.14 (5), p.e25496-e25496
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9246430
source Publicly Available Content (ProQuest); PubMed Central
subjects Adenosine
Antidiabetics
Beta blockers
Cancer therapies
Cohort analysis
Diabetes
Disease prevention
Endocrinology/Diabetes/Metabolism
Epidermal growth factor
Kinases
Medical prognosis
Meta-analysis
Obesity
Oncology
Pancreatic cancer
Pharmaceuticals
Preventive Medicine
Vascular endothelial growth factor
title An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Update%20on%20Common%20Pharmaceuticals%20in%20the%20Prevention%20of%20Pancreatic%20Cancer&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Miyaki,%20Candace&rft.date=2022-05-30&rft.volume=14&rft.issue=5&rft.spage=e25496&rft.epage=e25496&rft.pages=e25496-e25496&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.25496&rft_dat=%3Cproquest_pubme%3E2687722264%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c319t-52f9f9251953b3a21fa4795259c378c465f18c692f73fe4000fa80aa779995d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2696782244&rft_id=info:pmid/35800820&rfr_iscdi=true